Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2007, Pages

  Costello, Michael ^a   Shrestha, B ^b   Eden, J ^b   Sjoblom, P ^b   Johnson, N ^b  

^a ROYAL HOSPITAL FOR WOMEN   (Australia)

^b NONE

Author keywords

Acne vulgaris drug therapy ; Cardiovascular diseases prevention control ; Contraceptives, oral, combined *therapeutic use ; Endometrial neoplasms prevention control ; Hirsutism drug therapy

Indexed keywords

ANDROGEN; CHOLESTEROL; DIANE; DYDROGESTERONE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INOSITOL DERIVATIVE; INSULIN; INSULIN SENSITIZING AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; ROSIGLITAZONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL;

ACNE; ANDROGEN BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HIRSUTISM; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; MENSTRUATION; NAUSEA; OVARY POLYCYSTIC DISEASE; REVIEW; SIDE EFFECT; STROKE; SYSTEMATIC REVIEW; TESTOSTERONE BLOOD LEVEL; THORAX PAIN; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 35848938638     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005552.pub2     Document Type: Review

References (46)

1. Cibula 2005 {published data only} *Cibula D, Fanta M, Vrbikova J, Stanicka S, Dvorakova K, Hill M, Skrha J, Zivny J, Skrenkova J. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction 2005;20(1):180-4.
2. Elter 2002 {published data only} *Elter K, Imir G, Durmusoglu. Clinical, endocrine and metabolic effects of metformin added to ethinyl-estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction 2002;17(7):1729-37.
3. Harborne 2003 {published and unpublished data} *Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism 2003;88(9):4116- 23.
4. Morin-Papunen 2000 {published data only} *Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl-estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology & Metabolism 2000;85(9):3161-68.
5. Morin-Papunen 2003 {published data only} *Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiolcyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology & Metabolism 2003;88(1):148-56.
6. Rautio 2005 {published data only} *Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Effects ofmetformin and ethinyl-estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. European Journal of Endocrinology 2005;152:269-75.
7. Mitkov 2005 *Mitkov M, Pehlivanov B, Terzieva D. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome. European Journal of Obstetrics & Gynecology and Reproductive Biology 2005;118:209-13.
8. ACS 2003 American Cancer Society. Cancer facts & figures: 2003. American Cancer Society 2003.
9. Apridonidze 2005 Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of themetabolic syndrome in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism 2005;90:1929-35.
10. Azziz 2004 Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K, Boots LR. Androgen excess in women: experience with over 1000 consecutive patients. The Journal of Clinical Endocrinology and Metabolism 2004;89:453-62.
11. Baillargeon 2003 Baillargeon JP, Iuorno M, Nestler JE. Insulin sensitizers for polycystic ovary syndrome. Clinical Obstetrics and Gynecology 2003;46(2):325-40.
12. Checa 2005 Checa MA, Requena A, Salvador C, Tur R, Callejo J, Espinos JJ, Fabregues F, Herrero J. Insulin-senstizing agents: use in pregnancy and as therapy in polycystic ovary syndrome. Human Reproduction Update 2005;11:375-90.
13. Conway 1990 Conway GS, Jacobs HS, Holly JMP, Wass JA. Effects of luteinizing hormone, insulin, insulin-like growth factor-1 and insulin-like growth factor small binding protein-1 in the polycystic ovary syndrome. Clinical Endocrinology 1990;33:593-603.
14. Cook 1993 Cook DJ, Guyatt GH, Ryan G, Clifton J, Buckingham L, Willan A, McIlroy W, Oxman AD. Should unpublished data be included in meta-analyses? current convictions and controversies. Journal of American Medical Association 1993;269:2749-753.
15. Costello 2003 Costello MF, Eden JA. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertility and Sterility 2003;79:1-13.
16. Costello 2005 Costello MFC. Polycystic Ovary Syndrome: A Management Update. Australian Family Physician 2005;34:127-33.
17. Dahlgren 1991 Dahlgren E, Friberg LG, Johansson S, Lindstrom B, Oden A, Samsioe G, et al.Endometrial carcinoma; ovarian dysfunction - a risk factor in young women. European Journal of Obstetrics, Gynecology, & Reproductive Biology 1991;41(2):143-50.
18. Diam-Kandarakis 2003 Diamanti-Kandarakis E, Baillargeon, JP, Iuorno MJ, Jakubowicz DJ, Nestler JE. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. Journal of Clinical Endocrinology & Metabolism 2003;88:1927-32.
19. Dickersin 1987 Dickersin K, Chan S, Chalmers TC, Sacks HS, Smith H Jr. Publication bias and clinical trials. Controlled Clinical Trials 1987;8:343-53.
20. Dunaif 1989 Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-74.
21. Dunaif 1994 Dunaif A. Molecular mechanisms of insulin resistance in the polycystic ovary syndrome. Seminars in Reproductive Endocrinology 1994;12:15-20.
22. Eckel 2005 Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
23. Ehrmann 2003 Ehrmann DA, Rychlik D. Pharmacologic treatment of polycystic ovary syndrome. Seminars in Reproductive Medicine 2003;21(3):277-83.
24. Escobedo 1991 Escobedo LG, Lee NC, Peterson HB, Wingo PA. Infertility-associated endometrial cancer risk may be limited to specific subgroups of infertile women. Obstetrics & Gynecology 1991;77(1):124-8.
25. ESHRE/ASRM 2004 The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 2004;19:41-7.
26. Frank 1995 Frank S. Polycystic ovary syndrome. New England Journal of Medicine 1995;333:853-61.
27. Gallo 2005 Gallo MF, Nanda K, Grimes DA, Schulz KF. 20 mcg versus >20 mcg Estrogen combined oral contraceptives for contraception (Cochrane Review). Cochrane Database of Systematic Reviews 2005, Issue 2.Art. No.: CD003989. DOI:10.1002/14651858.CD003989.pub2.
28. Guyatt 1993 Guyatt GH, Sackett DL, Cook DJ. Users' Guides to the Medical Literature: II. How to Use an Article About Therapy or Prevention: A. Are the Results of the Study Valid?. Journal of American Medical Association 1993;270:2598-601.
29. Hardiman 2003 Hardiman P, Pillay OS, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003;361:1810-2.
30. Hasegawa 1999 Hasegawa I, Murakawa H, Suzuki M, Yamamoto Y, Kurabayashi T, Tanaka K. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertility and Sterility 1999;71:323-7.
31. Homburg 1996 Homburg R. Polycystic ovary syndrome - from gynaecological curiosity to multisystem endocrinopathy. Human Reproduction 1996;11:29-39.
32. Hughes 1996 Hughes EG. Systematic literature review and meta-analysis. Seminars in Reproductive Endocrinology 1996;14:161-9.
33. Hundal 2003 Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs 2003;63(18):1879-94.
34. Knowler 2002 Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine 2002;346:393-403.
35. Lord 2004 Lord JM, Flight IHK, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome (Cochrane Review). Cochrane Database of Systematic Reviews 2004, Issue 2.Art. No.: CD003053. DOI:10.1002/14651858. CD003053.
36. MIMS 2005 Monthly Index of Medical Specialities (MIMS). Monthly Index of Medical Specialities (Australia) 2005; Vol. 42, issue 2.
37. Nestler 2002 Nestler JE, Stovall D, Akhter N, Iuorno MJ, Jakubowicz MJ. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertility and Sterility 2002;77:209-15.
38. Ovalle 2002 Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertility and Sterility 2002;77:1095-1105.
39. Reaven 1999 Reaven GM. Insulin resistance: a chicken that has come to roost. Annuals of the New York Academy of Science 1999;892:45-57.
40. Rossouw 2002 Rossouw JE. Hormones, genetic factors, and gender differences in cardiovascular disease. Cardiovascular Research 2002;53(3):550-7.
41. Rotterdam ESHRE 2004 The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 2004;19:41-7.
42. UKPDS Group 1998 UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
43. Utiger 1996 Utiger R. Insulin and the polycystic ovary syndrome. New England Journal of Medicine 1996;335:657-8.
44. Vrbikova 2005 Vrbikova J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Human Reproduction Update 2005;11:277-91.
45. Wild 2002a Wild RA. Long-term health consequences of PCOS. Human Reproduction Update 2002;8:231-41.
46. Wild 2002b Wild RA. Polycystic ovary syndrome: a risk for coronary artery disease?. American Journal of Obstetrics & Gynaecology 2002;186:35-43.